Christian U. Blank

58.3k total citations · 11 hit papers
272 papers, 14.7k citations indexed

About

Christian U. Blank is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Christian U. Blank has authored 272 papers receiving a total of 14.7k indexed citations (citations by other indexed papers that have themselves been cited), including 235 papers in Oncology, 114 papers in Molecular Biology and 102 papers in Immunology. Recurrent topics in Christian U. Blank's work include Cancer Immunotherapy and Biomarkers (176 papers), CAR-T cell therapy research (113 papers) and Melanoma and MAPK Pathways (94 papers). Christian U. Blank is often cited by papers focused on Cancer Immunotherapy and Biomarkers (176 papers), CAR-T cell therapy research (113 papers) and Melanoma and MAPK Pathways (94 papers). Christian U. Blank collaborates with scholars based in Netherlands, United States and Australia. Christian U. Blank's co-authors include John B.A.G. Haanen, Andréas Mackensen, Ton N. Schumacher, Thomas F. Gajewski, Antoni Ribas, Elisa A. Rozeman, Georgina V. Long, Ian E. Brown, Jacob Schachter and Omid Hamid and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Christian U. Blank

261 papers receiving 14.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Defining ‘T cell exhaustion’

2019 953 citations Christian U. Blank, Ton N. Schumacher et al. profile →
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

2017 898 citations Antoni Ribas, Georgina V. Long et al. profile →
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

2019 768 citations Caroline Robert, Antoni Ribas et al. profile →
Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

2018 659 citations Alexander C. J. van Akkooi, Elisa A. Rozeman et al. profile →
PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

2004 609 citations Christian U. Blank, Ian E. Brown et al. profile →
The “cancer immunogram”

2016 540 citations Christian U. Blank, John B.A.G. Haanen et al. Science profile →
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

2017 504 citations Elisa A. Rozeman, Annegien Broeks et al. profile →
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

2013 499 citations Paolo A. Ascierto, Dirk Schadendorf et al. profile →
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

2014 427 citations Oscar Krijgsman, Paulien Cornelissen‐Steijger et al. profile →
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers

2019 372 citations Maartje W. Rohaan, Elisa A. Rozeman et al. Annals of Oncology profile →
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer

2021 195 citations Annegien Broeks, Christian U. Blank et al. profile →

Peers

Christian U. Blank

ONCOL

IMMUN

PRM

Jason J. Luke United States

Douglas B. Johnson United States

Michele W.L. Teng Australia

Richard D. Carvajal United States

Sergio A. Quezada United Kingdom

Ryan J. Sullivan United States

Steven O’Day United States

Matteo S. Carlino Australia

Taha Merghoub United States

Michael A. Postow United States

Jason J. Luke United States

Christian U. Blank

8.2k ×0.8

ONCOL

4.9k ×0.7

IMMUN

4.7k ×0.9

2.1k ×1.1

PRM

1.5k ×1.3

Citations per year, relative to Christian U. Blank Christian U. Blank (= 1×) peers Jason J. Luke

Countries citing papers authored by Christian U. Blank

Since Specialization

Citations

This map shows the geographic impact of Christian U. Blank's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christian U. Blank with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christian U. Blank more than expected).

Fields of papers citing papers by Christian U. Blank

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christian U. Blank. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christian U. Blank. The network helps show where Christian U. Blank may publish in the future.

Co-authorship network of co-authors of Christian U. Blank

This figure shows the co-authorship network connecting the top 25 collaborators of Christian U. Blank. A scholar is included among the top collaborators of Christian U. Blank based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christian U. Blank. Christian U. Blank is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vos, Joris L., Joleen J.H. Traets, Xiaohang Qiao, et al.. (2024). Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma. JCI Insight. 9(21). 5 indexed citations

Aarts, Maureen J.B., Franchette van den Berkmortel, Christian U. Blank, et al.. (2024). Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: Propensity score–matched recurrence-free, distant metastasis-free, and overall survival analysis.. Journal of Clinical Oncology. 42(16_suppl). 9573–9573. 1 indexed citations

Blank, Christian U., Richard A. Scolyer, Bart A. van de Wiel, et al.. (2024). Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.. Journal of Clinical Oncology. 42(17_suppl). LBA2–LBA2. 9 indexed citations

Menzies, Alexander M., Robyn P.M. Saw, Winan J. van Houdt, et al.. (2024). Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.. Journal of Clinical Oncology. 42(17_suppl). LBA9584–LBA9584.

Reijers, Irene L. M., Petros Dimitriadis, Alexander M. Menzies, et al.. (2023). 1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma. Annals of Oncology. 34. S660–S660. 2 indexed citations

Reijers, Irene L. M., Alexander M. Menzies, Judith M. Versluis, et al.. (2023). The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.. Journal of Clinical Oncology. 41(16_suppl). 101–101. 6 indexed citations

Burgmans, Mark C., Frank M. Speetjens, Arian R. van Erkel, et al.. (2023). Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial. CardioVascular and Interventional Radiology. 46(3). 350–359. 16 indexed citations

Hoeijmakers, Lianne, et al.. (2023). 1121P Interferon-gamma (IFNy) gene signature as a predictive biomarker for response in lactate dehydrogenase (LDH) low advanced melanoma patients. Annals of Oncology. 34. S674–S674.

Rao, Disha, Ruben Lacroix, Petros Dimitriadis, et al.. (2023). Acidity‐mediated induction of FoxP3 ⁺ regulatory T cells. European Journal of Immunology. 53(6). e2250258–e2250258. 17 indexed citations

10.

Lijnsvelt, J., Sanna Iivanainen, Maria Grazia Vitale, et al.. (2023). CN3 Patient adherence to digital patient-reported outcome monitoring (PROM) in cancer immunotherapies. Annals of Oncology. 34. S1226–S1227.

11.

Hoefsmit, Esmée P., Disha Rao, Petros Dimitriadis, et al.. (2023). Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells. Cancer Immunology Research. 11(4). 450–465. 10 indexed citations

12.

Serra-Bellver, Patricio, Judith M. Versluis, Cong Zhou, et al.. (2022). Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study. European Journal of Cancer. 176. 121–132. 14 indexed citations

13.

Gangaev, Anastasia, Elisa A. Rozeman, Maartje W. Rohaan, et al.. (2021). Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response. Proceedings of the National Academy of Sciences. 118(43). 21 indexed citations

14.

Krijgsman, Oscar, Kristel Kemper, Julia Boshuizen, et al.. (2021). Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4. Clinical Cancer Research. 27(19). 5389–5400. 3 indexed citations

15.

Reijers, Irene L. M., Elisa A. Rozeman, Sofie Wilgenhof, et al.. (2019). Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single‐centre experience in patients with BRAF‐mutated melanoma. Pigment Cell & Melanoma Research. 33(3). 498–506. 9 indexed citations

16.

Foppen, Marnix H. Geukes, Elisa A. Rozeman, Sandra van Wilpe, et al.. (2018). Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 3(1). e000278–e000278. 199 indexed citations

17.

Blank, Christian U., John B.A.G. Haanen, Antoni Ribas, & Ton N. Schumacher. (2016). The “cancer immunogram”. Science. 352(6286). 658–660. 540 indexed citations breakdown →

18.

Kemper, Kristel, Oscar Krijgsman, Paulien Cornelissen‐Steijger, et al.. (2015). Intra‐ and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts. EMBO Molecular Medicine. 7(9). 1104–1118. 103 indexed citations

19.

Kvistborg, Pia, Daisy Philips, Sander Kelderman, et al.. (2014). Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 ⁺ T cell response. Science Translational Medicine. 6(254). 254ra128–254ra128. 288 indexed citations

20.

Kline, Justin, Ian E. Brown, Christian U. Blank, et al.. (2008). Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma. Clinical Cancer Research. 14(10). 3156–3167. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact